

Angela Dziedzic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/460618/publications.pdf>

Version: 2024-02-01

19
papers

360
citations

759233

12
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

529
citing authors

#	ARTICLE	IF	CITATIONS
1	A Review of Various Antioxidant Compounds and their Potential Utility as Complementary Therapy in Multiple Sclerosis. <i>Nutrients</i> , 2019, 11, 1528.	4.1	65
2	miR-155 as an Important Regulator of Multiple Sclerosis Pathogenesis. A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4332.	4.1	33
3	Metformin as a Potential Agent in the Treatment of Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5957.	4.1	31
4	Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis. <i>Cells</i> , 2019, 8, 110.	4.1	29
5	Flavonolignans reduce the response of blood platelet to collagen. <i>International Journal of Biological Macromolecules</i> , 2018, 106, 878-884.	7.5	27
6	The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1804.	4.1	24
7	Increased level of fibrinogen chains in the proteome of blood platelets in secondary progressive multiple sclerosis patients. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3476-3482.	3.6	21
8	The GPR17 Receptor—A Promising Goal for Therapy and a Potential Marker of the Neurodegenerative Process in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1852.	4.1	16
9	Th17-Related Cytokines as Potential Discriminatory Markers between Neuromyelitis Optica (Devic's Disease) and Multiple Sclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1078-1087.	4.1	16
10	Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets. <i>Molecules</i> , 2018, 23, 374.	3.8	15
11	Interactions between platelets and leukocytes in pathogenesis of multiple sclerosis. <i>Advances in Clinical and Experimental Medicine</i> , 2019, 28, 277-285.	1.4	14
12	Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing-Remitting from Secondary Progressive Multiple Sclerosis. A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11887.	4.1	13
13	Flavonolignans Inhibit IL1- β -Induced Cross-Talk between Blood Platelets and Leukocytes. <i>Nutrients</i> , 2017, 9, 1022.	4.1	12
14	Increased Pro-Thrombotic Platelet Activity Associated with Thrombin/PAR1-Dependent Pathway Disorder in Patients with Secondary Progressive Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7722.	4.1	11
15	Unusual Bioactive Compounds with Antioxidant Properties in Adjuvant Therapy Supporting Cognition Impairment in Age-Related Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10707.	4.1	8
16	Oxidative Damage of Blood Platelets Correlates with the Degree of Psychophysical Disability in Secondary Progressive Multiple Sclerosis. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-12.	4.0	7
17	The Molecular Aspects of Disturbed Platelet Activation through ADP/P2Y12 Pathway in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6572.	4.1	6
18	Variations in the Gene Expression Profile in Atherosclerotic Patients with Non-Fatal ACS: A Preliminary Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5017.	4.1	1

#	ARTICLE	IF	CITATIONS
19	Editorial. VI PhD Students National Conference of Life Sciences "BioOpen". Acta Universitatis Lodzianis Folia Biologica Et Oecologica, 0, 17, 5-6.	1.0	0